Shield Therapeutics.
32 announcements.
32 announcements.
Time | Date | Ticker | Company | Announcement |
---|---|---|---|---|
07:00 | 21-02-2024 | STX | Shield Therapeutics | Unaudited Full Year Trading Update |
07:00 | 09-01-2024 | STX | Shield Therapeutics | Appointment of new Chief Financial Officer |
07:00 | 07-12-2023 | STX | Shield Therapeutics | Q3 2023 U.S. Commercial Highlights |
17:24 | 27-11-2023 | STX | Shield Therapeutics | PDMR Transaction Notification |
07:30 | 15-11-2023 | STX | Shield Therapeutics | Hardman & Co Research on Shield Therapeutics (STX): Accelerating effectiveness of enlarged sales team |
07:00 | 12-10-2023 | STX | Shield Therapeutics | Chief Financial Officer Transition |
15:00 | 03-10-2023 | STX | Shield Therapeutics | Result of REX Retail Offer |
07:00 | 03-10-2023 | STX | Shield Therapeutics | Block listing Interim Return |
07:00 | 03-10-2023 | STX | Shield Therapeutics | Completion of SWK Financing |
12:50 | 28-09-2023 | STX | Shield Therapeutics | Successful completion of US$6.1m Equity Fundraise |
07:02 | 28-09-2023 | STX | Shield Therapeutics | REX Retail Offer |
07:01 | 28-09-2023 | STX | Shield Therapeutics | $20m secured debt facility &proposed equity raise |
07:00 | 28-09-2023 | STX | Shield Therapeutics | Interim results update and business update |
07:00 | 06-09-2023 | STX | Shield Therapeutics | Notice of Results and Change in reporting currency |
09:45 | 25-07-2023 | STX | Shield Therapeutics | Hardman & Co Research on Shield Therapeutics (STX): Accrufer Rx momentum gathering |
07:00 | 20-07-2023 | STX | Shield Therapeutics | Business Update and U.S. Q2 2023 Highlights |
17:30 | 28-06-2023 | STX | Shield Therapeutics | Results of 2023 Annual General Meeting |
16:35 | 15-06-2023 | STX | Shield Therapeutics | Lapse of Offer |
07:00 | 15-06-2023 | STX | Shield Therapeutics | Acceptance Level Update |
07:00 | 14-06-2023 | STX | Shield Therapeutics | Acceptance Level Update |
07:00 | 13-06-2023 | STX | Shield Therapeutics | Acceptance Level Update |
07:00 | 12-06-2023 | STX | Shield Therapeutics | Acceptance Level Update |
07:00 | 09-06-2023 | STX | Shield Therapeutics | Acceptance Level Update |
07:00 | 08-06-2023 | STX | Shield Therapeutics | Acceptance Level Update |
10:10 | 06-06-2023 | STX | Shield Therapeutics | Grant of share options to the CEO |
11:00 | 01-06-2023 | STX | Shield Therapeutics | Holding(s) in Company |
10:55 | 01-06-2023 | STX | Shield Therapeutics | Holding(s) in Company |
07:00 | 31-05-2023 | STX | Shield Therapeutics | Total Voting Rights |
16:44 | 25-05-2023 | STX | Shield Therapeutics | Publication and posting of Offer Document |
07:00 | 19-05-2023 | STX | Shield Therapeutics | 2022 Annual Report and 2023 AGM Notice |
07:15 | 17-05-2023 | STX | Shield Therapeutics | Hardman & Co Research on Shield Therapeutics (STX): Reassuring 1Q’23 Accrufer prescriptions |
16:00 | 09-05-2023 | STX | Shield Therapeutics | Rule 2.9 Announcement and TVR Update |